Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1678)	5/5/2006 4:14:20 PM
From: Jibacoa	Respond to of 3722

BHIP Which is not a true Pharma or Biotech company, but sells "nutritional products" and "antioxidants" among other things.<g> Is also having an spike today. bigcharts.marketwatch.com It is trying to get off from its nearterm downtrend coming from its January 30 H at 12.09 <g> bigcharts.marketwatch.com Last month it requested a hearing with the NASDAQ concerning its failure to file its Annual 10-K in a timely fashion.<g> The stock trades around 0.97xBV the insiders reportedly hold more than 20% The 3rdQ results showed an improvement on revenues (+43%) but much lower earnings ($0.01/shr vs. $0.75/shr) & the 4thQ results are still unreported.<g> BHIP also has an "interesting" LTC. (the H 1n 1997 was 23,000 on an adjusted basis. <g>) bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (1678)	12/21/2006 10:31:31 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

PRCS Is having a good UG today with volume now over 1,421,280 after GSK announced it was planning to acquire it for $5 <g> bigcharts.marketwatch.com On today's Palm Beach Post there is an article by Stephen Pounds pointing out the need of large drug companies which are flush with cash, to look for acquiring some of the smaller biotechs with promising research programs but lacking cash resources.<g> PRCS had a deal with GILD in March to identify drug candidates for antiviral agents.<g> GILD has had 4 consecutive Qs of double digit improvement on revenues & EE for 2006 are around $2.40/shr vs, the $1.66 in 2005 Further improvements are expected in 2007. GILD closed its Oct.2 DG & found resistance at the $70 level.It is now trying toget off from its nearterm downtrend coming from its Nov 20 H at $70 after having found apparent support at the 63.20 level.<g> bigcharts.marketwatch.com Bernard